35. Continuous manufacturing in drug development, Matthew Bio, CEO, Snapdragon Chemistry

Dr. Matthew Bio is President & CEO at Snapdragon Chemistry. Matthew began his career in chemistry more than 20 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories. In 2006 Matthew moved to Amgen where he worked on the development of both batch and continuous processes, and drove innovation in technologies for the manufacture of synthetic – biologic hybrid molecules. In 2015, Matthew joined Snapdragon Chemistry, Inc., a contract development firm specialized in the design of continuous manufacturing technology. Throughout his career, Matthew has been involved in the development of more than 50 clinical candidates and the launch of three new drugs to the market. He is author or inventor on more than 30 peer reviewed publications and patents and numerous regulatory filings. Matthew is driven by a passion for the development of new technologies in organic synthesis to enable safer, more efficient processes and providing access to new chemical architectures.